The Chosun Ilbo on MSN10h
Korean biotech firms race into $26 billion U.S. biosimilar market
South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...
JD Supra20h
Celltrion Launches STEQEYMA® (ustekinumab-stba) in the United States
Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...